$VNDA
Vanda Pharmaceuticals Inc.

2014 Q4 Form 10-Q Financial Statement

#000119312514382267 Filed on October 27, 2014

View on sec.gov

Income Statement

Concept 2014 Q4 2014 Q3 2013 Q3
Revenue $15.37M $14.78M $8.709M
YoY Change 75.0% 69.73% 5.08%
Cost Of Revenue $680.0K $703.0K
YoY Change
Gross Profit $14.69M $14.08M
YoY Change
Gross Profit Margin 95.56% 95.24%
Selling, General & Admin $17.32M $11.29M $5.741M
YoY Change 74.42% 96.66% 82.25%
% of Gross Profit 117.92% 80.19%
Research & Development $4.750M $3.701M $8.022M
YoY Change -24.24% -53.86% -21.04%
% of Gross Profit 32.34% 26.29%
Depreciation & Amortization $700.0K $600.0K $500.0K
YoY Change 40.0% 20.0% 0.0%
% of Gross Profit 4.77% 4.26%
Operating Expenses $22.62M $14.99M $13.76M
YoY Change 36.51% 8.92% 35.48%
Operating Profit $69.69M -$1.448M -$5.431M
YoY Change -994.53% -73.34% 0.67%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $30.00K $20.00K $30.00K
YoY Change -25.0% -33.33% -57.14%
Pretax Income $69.72M -$1.430M -$5.380M
YoY Change -999.61% -73.42% 1.01%
Income Tax $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings $69.72M -$1.426M -$5.406M
YoY Change -999.95% -73.62% 1.5%
Net Earnings / Revenue 453.6% -9.65% -62.07%
Basic Earnings Per Share $1.85 -$0.04 -$0.17
Diluted Earnings Per Share $1.77 -$0.04 -$0.17
COMMON SHARES
Basic Shares Outstanding 33.90M shares 33.88M shares 31.33M shares
Diluted Shares Outstanding 31.33M shares

Balance Sheet

Concept 2014 Q4 2014 Q3 2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $129.8M $56.09M $142.2M
YoY Change -0.41% -60.56% 5.8%
Cash & Equivalents $60.90M $15.31M $142.2M
Short-Term Investments $68.92M $40.78M $0.00
Other Short-Term Assets $154.0K $182.0K $2.900M
YoY Change 20.31% -93.72% -23.68%
Inventory $5.170M $1.268M $0.00
Prepaid Expenses
Receivables $3.654M $3.696M $1.956M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $141.7M $64.84M $147.1M
YoY Change 4.51% -55.91% 5.13%
LONG-TERM ASSETS
Property, Plant & Equipment $2.437M $2.233M $2.106M
YoY Change 10.87% 6.03% -12.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $28.00K $800.0K $500.0K
YoY Change -94.4% 60.0% -16.67%
Total Long-Term Assets $29.97M $14.34M $8.020M
YoY Change 287.51% 78.77% -18.99%
TOTAL ASSETS
Total Short-Term Assets $141.7M $64.84M $147.1M
Total Long-Term Assets $29.97M $14.34M $8.020M
Total Assets $171.7M $79.18M $155.1M
YoY Change 19.78% -48.95% 3.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $835.0K $547.0K $369.0K
YoY Change 26.32% 48.24% -66.45%
Accrued Expenses $6.951M $6.825M $4.532M
YoY Change 34.19% 50.6% -33.35%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.786M $38.85M $31.91M
YoY Change -76.3% 21.75% -7.79%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.101M $113.0K $73.20M
YoY Change -95.33% -99.85% -26.65%
Total Long-Term Liabilities $3.101M $113.0K $73.20M
YoY Change -95.33% -99.85% -26.65%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.786M $38.85M $31.91M
Total Long-Term Liabilities $3.101M $113.0K $73.20M
Total Liabilities $10.89M $78.11M $105.1M
YoY Change -89.03% -25.67% -21.87%
SHAREHOLDERS EQUITY
Retained Earnings -$288.0M -$357.7M -$303.7M
YoY Change -6.55% 17.77%
Common Stock $448.8M $358.8M $353.7M
YoY Change 27.4% 1.42%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $160.8M $1.063M $50.00M
YoY Change
Total Liabilities & Shareholders Equity $171.7M $79.18M $155.1M
YoY Change 19.78% -48.95% 3.53%

Cashflow Statement

Concept 2014 Q4 2014 Q3 2013 Q3
OPERATING ACTIVITIES
Net Income $69.72M -$1.426M -$5.406M
YoY Change -999.95% -73.62% 1.5%
Depreciation, Depletion And Amortization $700.0K $600.0K $500.0K
YoY Change 40.0% 20.0% 0.0%
Cash From Operating Activities -$13.40M -$7.600M -$10.20M
YoY Change 9.84% -25.49% 0.0%
INVESTING ACTIVITIES
Capital Expenditures -$400.0K $0.00 $0.00
YoY Change 300.0%
Acquisitions
YoY Change
Other Investing Activities -$28.20M $5.800M $0.00
YoY Change -57.01% -100.0%
Cash From Investing Activities -$28.50M $5.700M $0.00
YoY Change -56.62% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $62.30M $48.50M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 87.50M 200.0K 48.80M
YoY Change 17400.0% -99.59%
NET CHANGE
Cash From Operating Activities -13.40M -7.600M -10.20M
Cash From Investing Activities -28.50M 5.700M 0.000
Cash From Financing Activities 87.50M 200.0K 48.80M
Net Change In Cash 45.60M -1.700M 38.60M
YoY Change -158.91% -104.4% 282.18%
FREE CASH FLOW
Cash From Operating Activities -$13.40M -$7.600M -$10.20M
Capital Expenditures -$400.0K $0.00 $0.00
Free Cash Flow -$13.00M -$7.600M -$10.20M
YoY Change 7.44% -25.49% 0.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q1 vnda Operating Lease Commitment Annual Rent
OperatingLeaseCommitmentAnnualRent
400000
CY2013Q3 us-gaap Deferred Revenue
DeferredRevenue
97027000
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
142172000
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33901084 shares
CY2014Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33901084 shares
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2014Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2014Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
323000
CY2014Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
36235000
CY2014Q3 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
241000
CY2014Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
8700000
CY2014Q3 us-gaap Liabilities Current
LiabilitiesCurrent
38845000
CY2014Q3 us-gaap Common Stock Value
CommonStockValue
34000
CY2014Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4000
CY2014Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
547000
CY2014Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-357703000
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1538000
CY2014Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
358728000
CY2014Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6825000
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
1063000
CY2014Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
113000
CY2014Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1257000
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
14974000
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1576000
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1500000
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
79175000
CY2014Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2454000
CY2014Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
31232000
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1337000
CY2014Q3 us-gaap Liabilities
Liabilities
78112000
CY2014Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1593000
CY2014Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
2919000
CY2014Q3 us-gaap Deferred Revenue
DeferredRevenue
67467000
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15308000
CY2014Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
411000
CY2014Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2233000
CY2014Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
40781000
CY2014Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3785000
CY2014Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
785000
CY2014Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
11319000
CY2014Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
411000
CY2014Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
796000
CY2014Q3 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
5818000
CY2014Q3 us-gaap Assets
Assets
79175000
CY2014Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
40781000
CY2014Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
2144000
CY2014Q3 us-gaap Inventory Net
InventoryNet
1268000
CY2014Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
213000
CY2014Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3696000
CY2014Q3 us-gaap Other Assets Current
OtherAssetsCurrent
182000
CY2014Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2508000
CY2014Q3 us-gaap Prepaid Insurance
PrepaidInsurance
487000
CY2014Q3 us-gaap Supplies
Supplies
608000
CY2014Q3 us-gaap Assets Current
AssetsCurrent
64838000
CY2014Q3 us-gaap Deferred Costs Current And Noncurrent
DeferredCostsCurrentAndNoncurrent
252000
CY2014Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
535000
CY2014Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
2000000
CY2014Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
7000
CY2014Q3 vnda Number Of Stock Incentive Plans
NumberOfStockIncentivePlans
2 EquityPlan
CY2014Q3 vnda Liabilities Recorded Contractual Obligations Relating To License Agreements
LiabilitiesRecordedContractualObligationsRelatingToLicenseAgreements
0
CY2014Q3 vnda Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
1521000
CY2014Q3 vnda Liabilities Recorded Future License Payments
LiabilitiesRecordedFutureLicensePayments
0
CY2014Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
33901084 shares
CY2012Q4 us-gaap Deferred Revenue
DeferredRevenue
117064000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
88772000
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33338543 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33338543 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
63486000
CY2013Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
221000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
32851000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
33000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
21000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
661000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-308170000
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
352240000
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5180000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
44124000
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
665000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
143349000
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2015000
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
26789000
CY2013Q4 us-gaap Liabilities
Liabilities
99225000
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
176000
CY2013Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
2888000
CY2013Q4 us-gaap Deferred Revenue
DeferredRevenue
90275000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64764000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2198000
CY2013Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
530000
CY2013Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
65586000
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2703000
CY2013Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
500000
CY2013Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
5037000
CY2013Q4 us-gaap Assets
Assets
143349000
CY2013Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
65586000
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2031000
CY2013Q4 us-gaap Other Assets Current
OtherAssetsCurrent
128000
CY2013Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2408000
CY2013Q4 us-gaap Prepaid Insurance
PrepaidInsurance
167000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
135614000
CY2013Q4 vnda Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
2324000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.63 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.98
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-27439000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29363162 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.45
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y11D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0128 pure
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1555000
us-gaap Other Income
OtherIncome
101000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4504339 shares
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-10000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-10000
us-gaap Licenses Revenue
LicensesRevenue
20037000
us-gaap Operating Income Loss
OperatingIncomeLoss
-13409000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-121000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13318000
us-gaap Royalty Revenue
RoyaltyRevenue
5059000
us-gaap Revenues
Revenues
25096000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
79000
us-gaap Net Income Loss
NetIncomeLoss
-13308000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
788000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
196000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3947000
us-gaap Deferred Revenue Revenue Recognized
DeferredRevenueRevenueRecognized
20037000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
321000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-20037000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22233000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
15154000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1118000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
53400000
us-gaap Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions
1062000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
49418000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
48552000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-655000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
31421000
us-gaap Advertising Expense
AdvertisingExpense
0
us-gaap Costs And Expenses
CostsAndExpenses
38505000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
800000
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
82000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
31500000
us-gaap Share Based Compensation
ShareBasedCompensation
3997000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
155000
us-gaap Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
32386 shares
dei Document Type
DocumentType
10-Q
dei Entity Registrant Name
EntityRegistrantName
Vanda Pharmaceuticals Inc.
dei Trading Symbol
TradingSymbol
VNDA
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.64 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.14
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y10M24D
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-68168000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M2D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0176 pure
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <b><i>Use of estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> </div>
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
33814154 shares
dei Document Period End Date
DocumentPeriodEndDate
2014-09-30
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
dei Entity Central Index Key
EntityCentralIndexKey
0001347178
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.46
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3779497 shares
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
40383000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-245000
us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
173000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2678000
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
6888000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-17000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-17000
us-gaap Licenses Revenue
LicensesRevenue
22981000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1082000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1268000
us-gaap Other Income
OtherIncome
98000
us-gaap Operating Income Loss
OperatingIncomeLoss
-49631000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-132000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-49550000
us-gaap Royalty Revenue
RoyaltyRevenue
4919000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
8000000
us-gaap Revenues
Revenues
34788000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
431000
us-gaap Net Income Loss
NetIncomeLoss
-49533000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1665000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4247000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
436000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4153000
us-gaap Deferred Revenue Revenue Recognized
DeferredRevenueRevenueRecognized
22981000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
396000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-49456000
us-gaap Cost Of Goods Sold
CostOfGoodsSold
901000
us-gaap Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions
2677000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2241000
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
436000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1645000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
16471000
us-gaap Advertising Expense
AdvertisingExpense
4600000
us-gaap Costs And Expenses
CostsAndExpenses
84419000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-22808000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14479000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
67321000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
1400000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1718000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1200000
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-114000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
56092000
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
8948000
us-gaap Share Based Compensation
ShareBasedCompensation
4247000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
164000
vnda Share Based Compensation Option Awards Contractual Term
ShareBasedCompensationOptionAwardsContractualTerm
P10Y
vnda Share Based Compensation Arrangement By Share Based Payment Award Remaining Percentage Of Share Subject To Option Awards
ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards
0.75 pure
vnda Percentage Of Responsibility For Patients Cost Of Branded Prescription
PercentageOfResponsibilityForPatientsCostOfBrandedPrescription
0.50 pure
vnda Initial Stock Options Granted To Directors Vesting And Exercisable Period
InitialStockOptionsGrantedToDirectorsVestingAndExercisablePeriod
P4Y
vnda Deferred Revenue Recognition Period
DeferredRevenueRecognitionPeriod
P45D
vnda Option Awards Vesting Period After Completion Of One Year Of Service
OptionAwardsVestingPeriodAfterCompletionOfOneYearOfService
P3Y
vnda Sharebased Compensation Arrangement By Sharebased Payment Award Restricted Stock Units Or Non Vested Shares Vesting Period1
SharebasedCompensationArrangementBySharebasedPaymentAwardRestrictedStockUnitsOrNonVestedSharesVestingPeriod1
P4Y
vnda Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Share Subject To Option Awards
ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards
0.25 pure
vnda Subsequent Stock Options Granted To Directors Vesting And Exercisable Period
SubsequentStockOptionsGrantedToDirectorsVestingAndExercisablePeriod
P1Y
CY2004Q1 vnda Percentage Of Future Sublicense Fees Payable
PercentageOfFutureSublicenseFeesPayable
Mid-twenties
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31332993 shares
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
CY2013Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3517934 shares
CY2013Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
CY2013Q3 us-gaap Licenses Revenue
LicensesRevenue
6753000
CY2013Q3 us-gaap Other Income
OtherIncome
25000
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5431000
CY2013Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5406000
CY2013Q3 us-gaap Royalty Revenue
RoyaltyRevenue
1956000
CY2013Q3 us-gaap Revenues
Revenues
8709000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-5406000
CY2013Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1536000
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8022000
CY2013Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5741000
CY2013Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
377000
CY2013Q3 us-gaap Costs And Expenses
CostsAndExpenses
14140000
CY2013Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
300000
CY2013Q3 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
33886845 shares
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2014Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3728109 shares
CY2014Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
5329000
CY2014Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-6000
CY2014Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-6000
CY2014Q3 us-gaap Licenses Revenue
LicensesRevenue
7764000
CY2014Q3 us-gaap Other Income
OtherIncome
22000
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1448000
CY2014Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1432000
CY2014Q3 us-gaap Royalty Revenue
RoyaltyRevenue
1689000
CY2014Q3 us-gaap Revenues
Revenues
14782000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-1426000
CY2014Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1392000
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3701000
CY2014Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11290000
CY2014Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
536000
CY2014Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
703000
CY2014Q3 us-gaap Advertising Expense
AdvertisingExpense
300000
CY2014Q3 us-gaap Costs And Expenses
CostsAndExpenses
16230000
CY2014Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
400000
CY2014Q3 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax

Files In Submission

Name View Source Status
0001193125-14-382267-index-headers.html Edgar Link pending
0001193125-14-382267-index.html Edgar Link pending
0001193125-14-382267.txt Edgar Link pending
0001193125-14-382267-xbrl.zip Edgar Link pending
d784389d10q.htm Edgar Link pending
d784389dex311.htm Edgar Link pending
d784389dex312.htm Edgar Link pending
d784389dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vnda-20140930.xml Edgar Link completed
vnda-20140930.xsd Edgar Link pending
vnda-20140930_cal.xml Edgar Link unprocessable
vnda-20140930_def.xml Edgar Link unprocessable
vnda-20140930_lab.xml Edgar Link unprocessable
vnda-20140930_pre.xml Edgar Link unprocessable